Amylyx Pharmaceuticals, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-210292
- Form type
- 10-Q
- CIK
- 0001658551
- Primary document
- https://www.sec.gov/Archives/edgar/data/1658551/000119312526210292/amlx-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Amylyx Pharmaceuticals, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-43.8M | - | - |
| Net Income | $-41.3M | - | - |
| Eps Basic | -0.37 | - | - |
| Eps Diluted | -0.37 | - | - |
| Cash And Equivalents | $229.1M | - | - |
| Total Assets | $293.6M | - | - |
| Total Liabilities | $20.4M | - | - |
| Shareholders Equity | $273.2M | - | - |
| Operating Cash Flow | $-36.9M | - | - |
| Capital Expenditures | $11,000 | - | - |